Evidence map›Paper›PMID 38703389›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression.

Helen L Zhang, Meredith Mock, Lane Bushman, Peter L Anderson, Jennifer J Kiser, Susanna Naggie

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Hepatitis B virus (HBV) viremia despite tenofovir disoproxil fumarate-containing antiretroviral therapy in persons with HBV/HIV coinfection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Helen L ZhangHospital Medicine Section, Medicine Specialty Service, Durham VA Medical Center, Durham, North Carolina, USA.ORCID 0000-0001-8978-1832
Meredith MockDepartment of Physician Assistant Studies, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA.
Lane BushmanDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
Peter L AndersonDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
Jennifer J KiserDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Anschutz Medical Campus, Aurora, Colorado, USA.
Susanna NaggieDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Funding

Infectious Diseases Epidemiology Training GrantT32AI055435 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LAUTENBACH, EBBING · 2003 to 2023
$6.9M
National Institute of Allergy and Infectious Diseases T32-AI055435-17NIAID NIH HHS T32 AI055435NIH
6 · The paper itself

Abstract

This case-control study explored cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatis B virus (HIV/HBV) coinfection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were ∼3-fold lower among patients with incomplete HBV viral suppression (n = 4) compared to those with complete suppression (n = 5) (516 vs 1456 fmol/punch).

Indexed as

CoinfectionHepatitis BHIV InfectionsTenofovirViral LoadAdultAnti-HIV AgentsAntiviral AgentsCase-Control StudiesFemaleHepatitis B virusHumansMaleMiddle AgedAnti-HIV AgentsAntiviral AgentsTenofoviradherenceantiretroviral therapydried blood spotstenofovir-diphosphatevirologic failure

Identifiers

PMID38703389
PMCPMC11426266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.